6 August 2021 - - US-based generic and brand pharmaceutical company Amring Pharmaceuticals Inc has received FDA approval for generic Isoproterenol Hydrochloride USP, (0.2 mg/mL) available as 1 mL or 5 mL Single-Dose Vials, (AP rated generic equivalent of Isuprel), and has immediately begun commercialization activity, the company said.

Isoproterenol Hydrochloride Injection USP is indicated for mild or transient episodes of heart block that do not require electric shock or pacemaker therapy; for serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation); for use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available; for bronchospasm occurring during anesthesia; and as an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock.

Amring Pharmaceuticals is a privately held pharmaceutical company that provides niche generics and value-driven brands to the market.

The company is a subsidiary of Sever Life Sciences B.V., a global private specialty pharmaceutical company based in the Netherlands.

Amring is partnered with well-established global biopharmaceutical companies, and is uniquely positioned to leverage its expertise in bringing biotechnology derived medicines, sterile manufacturing and other state-of-the-art technologies to the marketplace.

Sever Life Sciences B.V. is a global private specialty pharmaceutical holding company committed to helping people around the world live better lives.

Headquartered in the Netherlands, Sever Life Sciences B.V. unites 4 separate pharmaceutical businesses, Nordic Pharma, Amring USA, Izvarino, and Sever Pharma Solutions (QPharma and Disphar). They cover an interesting and diverse range of pharmaceutical products, business models, markets, and capabilities.